Cost/effectiveness of elivaldogene autotemcel vs. hematopoietic stem cells transplantation in patients with cerebral adrenoleukodystrophy (CALD)

References

• Berger J, Forss-Petter S, Eichler FS. Pathophysiology of X-linked adrenoleukodystrophy. Biochimie. 2014;98(100):1–10. doi: 10.1016/j.biochi.2013.11.023.
   PubMedGoogle Scholar
• Berger J, Gärtner J. X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta. 2006;1763(12):1721–1732. doi: 10.1016/j.bbamcr.2006.07.010.
   PubMed Web of Science ®Google Scholar
• Jardim LB, da Silva ACF, Blank D, et al. X-linked adrenoleukodystrophy: clinical course and minimal incidence in South Brazil. Brain Dev. 2010;32(3):180–190. doi: 10.1016/j.braindev.2009.02.002.
   PubMed Web of Science ®Google Scholar
• Zhu J, Eichler F, Biffi A, et al. The changing face of adrenoleukodystrophy. Endocr Rev. 2020;41(4):577–593. doi: 10.1210/endrev/bnaa013.
   PubMed Web of Science ®Google Scholar
• Raymond GV, Aubourg P, Paker A, et al. Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(3):538–548. doi: 10.1016/j.bbmt.2018.09.036.
   PubMed Web of Science ®Google Scholar
• Miller WP, Rothman SM, Nascene D, et al. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood. 2011;118(7):1971–1978. doi: 10.1182/blood-2011-01-329235.
   PubMed Web of Science ®Google Scholar
• Eichler F, Duncan C, Musolino PL, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377(17):1630–1638. doi: 10.1056/NEJMoa1700554.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Elivaldogene autotemcel: first approval. Mol Diagn Ther. 2021;25(6):803–809. doi: 10.1007/s40291-021-00555-1.
   PubMed Web of Science ®Google Scholar
• Larkin HD. Autologous gene therapy approved for childhood CALD. JAMA. 2022;328(17):1679–1680. doi: 10.1001/jama.2022.19800.
   Web of Science ®Google Scholar
• Skysona | European Medicines Agency [Internet]; [cited 2024 Feb 24]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/skysona#ema-inpage-item-news-on
   Google Scholar
• Schreiber-Katz O, Klug C, Thiele S, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9(1):210. doi: 10.1186/s13023-014-0210-9.
   PubMedGoogle Scholar
• Winquist E, Bell CM, Clarke JTR, et al. An evaluation framework for funding drugs for rare diseases. Value Health. 2012;15(6):982–986. doi: 10.1016/j.jval.2012.06.009.
   PubMed Web of Science ®Google Scholar
• Karnon J, Haji Ali Afzali H. When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES. Pharmacoeconomics. 2014;32(6):547–558. doi: 10.1007/s40273-014-0147-9.
   PubMed Web of Science ®Google Scholar
• Gutić M, Milosavljević MN, Janković SM. Cost-effectiveness of miglustat versus symptomatic therapy of Niemann–Pick disease type C. Int J Clin Pharm. 2022;44(6):1442–1453. doi: 10.1007/s11096-022-01491-8.
   PubMed Web of Science ®Google Scholar
• Republic Health Insurance Fund of Serbia. Rulebook on the list of medicines prescribed and issued at the expense of compulsory health insurance funds. Off Gaz RS. 440/2022, 144/2022, 40/2023, 57/2023, 66/2023, 67/2023, 86/2023, 104/2023 and 17/2024.
   Google Scholar
• The Government of the Republic of Serbia. Decision on the highest prices of prescription medicines for human use. Off Gaz RS. 48/2021.
   Google Scholar
• Eichler F, Duncan C, Orchard P, et al. Disease stabilization following treatment with elivaldogene autotemcel (eli-cel, Lenti-D) gene therapy for the treatment of cerebral adrenoleukodystrophy: interim results from phase 2/3 (ALD-102) and phase 3 (ALD-104) studies (2064). Neurology. 2021;96(15 Supplement).
   Google Scholar
• Suzuki Y, Imamura A, Shimozawa N, et al. The clinical course of childhood and adolescent adrenoleukodystrophy before and after Lorenzo’s oil. Brain Dev. 2001;23(1):30–33. doi: 10.1016/s0387-7604(00)00196-0.
   PubMed Web of Science ®Google Scholar
• Kühl JS, Suarez F, Gillett GT, et al. Long-term outcomes of allogeneic haematopoietic stem cell transplantation for adult cerebral X-linked adrenoleukodystrophy. Brain. 2017;140(4):953–966. doi: 10.1093/brain/awx016.
   PubMedGoogle Scholar
• Pierpont EI, Nascene DR, Shanley R, et al. Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy. Neurology. 2020;95(5):e591–e600. doi: 10.1212/WNL.0000000000009929.
   PubMed Web of Science ®Google Scholar
• Pereira FS, Matte U, Habekost CT, et al. Mutations, clinical findings and survival estimates in South American patients with X-linked adrenoleukodystrophy. PLoS One. 2012;7(3):e34195. doi: 10.1371/journal.pone.0034195.
   PubMed Web of Science ®Google Scholar
• Matos T, Costa C, Araújo AN, et al. Clinical course and endocrine dysfunction in X-linked adrenoleukodystrophy: a case series. Endocrinol Diabetes Nutr. 2023;70(6):421–428. doi: 10.1016/j.endinu.2022.01.007.
   Web of Science ®Google Scholar
• Kanakis G, Kaltsas G. Adrenal Insufficiency Due to X-Linked Adrenoleukodystrophy. [Updated 2018 Oct 12]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278944/.
   Google Scholar
• Tordrup D, Smith R, Kamenov K, et al. WHO HEAR group. Global return on investment and cost-effectiveness of WHO’s HEAR interventions for hearing loss: a modelling study. Lancet Glob Health. 2022;10(1):e52–e62. doi: 10.1016/S2214-109X(21)00447-2.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Gavriel S, et al. Health utility values associated with diabetic retinopathy. Diabet Med. 2008;25(5):618–624. doi: 10.1111/j.1464-5491.2008.02430.x.
   PubMed Web of Science ®Google Scholar
• Fattori A, Neri L, Aguglia E, et al. Estimating the impact of workplace bullying: humanistic and economic burden among workers with chronic medical conditions. Biomed Res Int. 2015;2015:708908–708912. doi: 10.1155/2015/708908.
   PubMed Web of Science ®Google Scholar
• Chittrakul J, Siviroj P, Sungkarat S, et al. Multi-system physical exercise intervention for fall prevention and quality of life in pre-frail older adults: a randomized controlled trial. Int J Environ Res Public Health. 2020;17(9):3102. doi: 10.3390/ijerph17093102.
   PubMed Web of Science ®Google Scholar
• Ozkan Y. Child’s quality of life and mother’s burden in spastic cerebral palsy: a topographical classification perspective. J Int Med Res. 2018;46(8):3131–3137. doi: 10.1177/0300060518772758.
   PubMed Web of Science ®Google Scholar
• Zhang P, Brown MB, Bilik D, et al. Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from translating research into action for diabetes (TRIAD). Diabetes Care. 2012;35(11):2250–2256. doi: 10.2337/dc11-2478.
   PubMed Web of Science ®Google Scholar
• López-Bastida J, Perestelo-Pérez L, Montón-Alvarez F, et al. Social economic costs and health-related quality of life in patients with degenerative cerebellar ataxia in Spain. Mov Disord. 2008;23(2):212–217. doi: 10.1002/mds.21798.
   PubMed Web of Science ®Google Scholar
• McDaid D, Park AL, Chadha S. Estimating the global costs of hearing loss. Int J Audiol. 2021;60(3):162–170. doi: 10.1080/14992027.2021.1883197.
   PubMed Web of Science ®Google Scholar
• Marques AP, Ramke J, Cairns J, et al. The economics of vision impairment and its leading causes: a systematic review. EClinicalMedicine. 2022;46:101354. doi: 10.1016/j.eclinm.2022.101354.
   PubMedGoogle Scholar
• Shahat ARS, Greco G. The economic costs of childhood disability: a literature review. Int J Environ Res Public Health. 2021;18(7):3531. doi: 10.3390/ijerph18073531.
   PubMed Web of Science ®Google Scholar
• de Lissovoy G, Matza LS, Green H, et al. Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy. J Child Neurol. 2007;22(1):49–59. doi: 10.1177/0883073807299976.
   PubMed Web of Science ®Google Scholar
• Beecham J, O’Neill T, Goodman R. Supporting young adults with hemiplegia: services and costs. Health Soc Care Community. 2001;9(1):51–59. doi: 10.1046/j.1365-2524.2001.00279.x.
   PubMed Web of Science ®Google Scholar
• Happich M, John J, Stamenitis S, et al. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002–results from the diabetic microvascular complications (DIMICO) study. Diabetes Res Clin Pract. 2008;81(2):223–230. doi: 10.1016/j.diabres.2008.03.019.
   PubMed Web of Science ®Google Scholar
• Liu A. A $3M gene therapy: bluebird bio breaks its own pricing record with FDA approval of Skysona [Internet]. Fierce Pharma. 2022; [cited 2023 Mar 30]. Available from: https://www.fiercepharma.com/pharma/3m-gene-therapy-bluebird-breaks-own-record-fda-approval-skysona
   Google Scholar
• Statistical Office of the Republic of Serbia 2022. [Internet]. [cited 2023 Apr 04]. Available from: https://data.stat.gov.rs/Home/Result/09020101?languageCode=sr-Cyrl
   Google Scholar
• National Bank of Serbia. Interest rates [Internet]. [cited 2023 Apr 04]. Available from: https://www.nbs.rs/sr/ciljevi-i-funkcije/monetarna-politika/kamatne-stope/
   Google Scholar
• Republic Health Insurance Fund of Serbia Rulebook on the prices of health services at the secondary and tertiary levels of health care. Off Gaz RS. 88/2021, 97/2021, 109/2021, 132/2021, 47/2022, 82/2022, 123/2022, 128/2022, 1/2023, 59/2023, 96/2023 and 15/2024.
   Google Scholar
• National Bank of Serbia. Average exchange rates [Internet]. [cited 2024 Mar 29]. Available from: https://nbs.rs/en/finansijsko_trziste/medjubankarsko-devizno-trziste/kursna-lista/prosecni-kursevi/index.html
   Google Scholar
• Gutić M, Milosavljević MN, Safiye T, et al. Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2). Expert Rev Pharmacoecon Outcomes Res. 2023;23(5):561–570. doi: 10.1080/14737167.2023.2197213.
   PubMed Web of Science ®Google Scholar
• Eunethta. PTJA17 – Core Submission Dossier for Elivaldogene autotemcel (eli-cel) for treatment of Cerebral Adrenoleukodystrophy (CALD) [Internet]. [cited 2023 May 20]. Available from: https://www.eunethta.eu/wp-content/uploads/2021/08/PTJA17-Eli-cel-Core-Submission-Dossier-v1.0.pdf
   Google Scholar
• Kuratsubo I, Suzuki Y, Shimozawa N, et al. Parents of childhood X-linked adrenoleukodystrophy: high risk for depression and neurosis. Brain Dev. 2008;30(7):477–482. doi: 10.1016/j.braindev.2007.12.012.
   PubMed Web of Science ®Google Scholar
• Paramore C, Dietz A, Boulanger L. PND48 costs of episodes of care for allogeneic transplant for the the treatment of cerebral adrenoleukodystrophy in the U.S. Value Health. 2020;23(suppl. 1):S268. doi: 10.1016/j.jval.2020.04.941.
   Google Scholar
• Kanters TA, van der Ploeg AT, Kruijshaar ME, et al. Cost- effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet J Rare Dis. 2017;12(1):179. doi: 10.1186/s13023-017-0731-0.
   PubMedGoogle Scholar
• Iskrov G, Stefanov R. Criteria for drug reimbursement decision-making: an emerging public health challenge in Bulgaria. Balkan Med J. 2016;33(1):27–35. doi: 10.5152/balkanmedj.2015.15185.
   PubMed Web of Science ®Google Scholar